LT3337820T - Patobulintas antikūnų fragmentų refoldingo būdas - Google Patents

Patobulintas antikūnų fragmentų refoldingo būdas

Info

Publication number
LT3337820T
LT3337820T LTEP16766389.7T LT16766389T LT3337820T LT 3337820 T LT3337820 T LT 3337820T LT 16766389 T LT16766389 T LT 16766389T LT 3337820 T LT3337820 T LT 3337820T
Authority
LT
Lithuania
Prior art keywords
fragments
antibody
refolding process
improved refolding
improved
Prior art date
Application number
LTEP16766389.7T
Other languages
English (en)
Inventor
Sandeep Somani
Ashish Pandey
Ashok Mishra
Rustom Mody
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of LT3337820T publication Critical patent/LT3337820T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEP16766389.7T 2015-08-17 2016-08-17 Patobulintas antikūnų fragmentų refoldingo būdas LT3337820T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3118MU2015 2015-08-17
PCT/IB2016/054926 WO2017029620A1 (en) 2015-08-17 2016-08-17 An improved refolding process for antibody's fragments

Publications (1)

Publication Number Publication Date
LT3337820T true LT3337820T (lt) 2021-02-10

Family

ID=56936450

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16766389.7T LT3337820T (lt) 2015-08-17 2016-08-17 Patobulintas antikūnų fragmentų refoldingo būdas

Country Status (19)

Country Link
US (1) US10781250B2 (lt)
EP (1) EP3337820B1 (lt)
JP (1) JP6755939B2 (lt)
CN (1) CN108026165A (lt)
AU (1) AU2016307976A1 (lt)
CA (1) CA2993907A1 (lt)
DK (1) DK3337820T3 (lt)
ES (1) ES2843558T3 (lt)
HK (1) HK1254752A1 (lt)
HR (1) HRP20210067T1 (lt)
HU (1) HUE052993T2 (lt)
LT (1) LT3337820T (lt)
MX (1) MX394263B (lt)
PH (1) PH12018500362B1 (lt)
PL (1) PL3337820T3 (lt)
PT (1) PT3337820T (lt)
RU (1) RU2018109102A (lt)
WO (1) WO2017029620A1 (lt)
ZA (1) ZA201801498B (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
MX2019011343A (es) * 2017-03-24 2019-11-18 Council Scient Ind Res Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
EP3624847A1 (en) * 2017-05-19 2020-03-25 Council of Scientific and Industrial Research A method for producing refolded recombinant humanized ranibizumab
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
CN111128293B (zh) * 2019-11-25 2020-11-10 苏州纽博立科技有限公司 一种抗体药物生产工艺中碎片的修复方法
CN113073092A (zh) * 2021-04-15 2021-07-06 宁波瑞林生物科技有限公司 重组人组织型激肽释放酶及其制备方法
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
WO2006058890A2 (en) * 2004-11-30 2006-06-08 Novo Nordisk A/S Method of producing antibodies
CN100336824C (zh) * 2005-12-19 2007-09-12 百奥泰生物科技(广州)有限公司 一种重组蛋白的高效变复性的方法
ES2603399T3 (es) * 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
CN101506222B (zh) * 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠
CN102089319B (zh) * 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
CN102206272B (zh) * 2009-12-11 2014-10-01 普罗特奥姆技术公司 生产重组α1-抗胰蛋白酶的方法
CA2815342A1 (en) * 2010-10-20 2012-04-26 Medimmune, Llc Methods for processing inclusion bodies
US10065987B2 (en) * 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
CN103804486B (zh) * 2014-01-20 2017-05-17 安徽安科生物工程(集团)股份有限公司 一种提高重组人干扰素α2b天然构象含率的制备工艺

Also Published As

Publication number Publication date
HRP20210067T1 (hr) 2021-03-05
MX2018001994A (es) 2018-11-09
ES2843558T3 (es) 2021-07-19
PL3337820T3 (pl) 2021-11-22
JP2018529654A (ja) 2018-10-11
HUE052993T2 (hu) 2021-06-28
RU2018109102A3 (lt) 2020-01-30
EP3337820B1 (en) 2020-10-14
JP6755939B2 (ja) 2020-09-16
EP3337820A1 (en) 2018-06-27
ZA201801498B (en) 2018-12-19
PH12018500362B1 (en) 2022-08-05
AU2016307976A1 (en) 2018-03-08
WO2017029620A1 (en) 2017-02-23
US10781250B2 (en) 2020-09-22
CA2993907A1 (en) 2017-02-23
PT3337820T (pt) 2021-01-19
DK3337820T3 (da) 2021-01-18
PH12018500362A1 (en) 2018-08-29
CN108026165A (zh) 2018-05-11
HK1254752A1 (zh) 2019-07-26
US20180230206A1 (en) 2018-08-16
RU2018109102A (ru) 2019-09-19
MX394263B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
ZA202003742B (en) Anti-lag3 antibodies and antigen-binding fragments
IL259048A (en) Antibodies against ror-1
IL247508A0 (en) A method for preparing human plasma proteins
SG10201913864RA (en) Anti-LAG-3 Antibodies
IL253633A0 (en) Anti-transthyretin antibodies
SG11201605580RA (en) Antibodies directed against interleukin-33 (il-33)
SG10202010735PA (en) Tau-binding antibodies
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
PL3250593T3 (pl) Przeciwciała przeciwko transtyretynie
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
IL273265A (en) New combinations for antigen-based therapy
SG11201706125QA (en) Anti-transthyretin antibodies
ZA201801498B (en) An improved refolding process for antibody's fragments
IL258981A (en) Methods for the production of proteins
EP3147368A4 (en) Method for producing fibroin-like protein
GB201509907D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201522394D0 (en) Antibodies
IL284022B1 (en) Anti-transthyretin antibodies
GB201518728D0 (en) Antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies